{"disease":{"id":"myelofibrosis-post-et","name":"myelofibrosis post et"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT06479135","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07357727","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03662126","title":"KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":385,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03441113","title":"Extended Access of Momelotinib in Adults With Myelofibrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":237,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT03402399","title":"Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":222,"lead_sponsor_name":"Assaf-Harofeh Medical Center","has_results":false},{"nct_id":"NCT02101268","title":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT04279847","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT01392443","title":"Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04640532","title":"KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":116,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03136185","title":"Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT06343805","title":"A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Ajax Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04217993","title":"Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT02515630","title":"Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT03895112","title":"MPN-RC 118 AVID200 in Myelofibrosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"John Mascarenhas","has_results":false},{"nct_id":"NCT05467800","title":"Study of Canakinumab in Patients With Myelofibrosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":14,"lead_sponsor_name":"John Mascarenhas","has_results":false},{"nct_id":"NCT03935555","title":"Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Samus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07340138","title":"Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04745637","title":"Managed Access Programs for INC424, Ruxolitinib","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}